Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1639 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

NicOx Releases Naproxcinod Phase 3 Blood Pressure Results

The study was presented by William White, professor of school of medicine at University of Connecticut. Naproxcinod is the CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug-candidate developed for the

AstraZeneca, Pozen Get FDA Nod For Vimovo

Vimovo, co-developed by Pozen and AstraZeneca, is a fixed-dose combination of delayed-release enteric-coated naproxen, a pain-relieving NSAID, and immediate-release esomeprazole, a proton pump inhibitor (PPI). Reportedly, the FDA